Thermo Fisher Scientific has completed the acquisition of cellular and genetic analysis products provider Affymetrix, for around $1.3bn.
As part of the deal, Thermo Fisher paid $14.00 per share to the stakeholders of Affymetrix.
The deal was first announced by both firms in January this year.
Earlier this month, Origin Technologies offered around $1.5bn to acquire US-based medical technology firm Affymetrix, topping a $1.3bn bid from Thermo Fisher Scientific.
Thermo Fisher Scientific president and CEO Marc Casper said: "With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets.
"Our combined capabilities will benefit our customers, employees and shareholders, and we are excited to move forward as one organization positioned for growth."
Affymetrix president and CEO Frank Witney said: "This transaction creates significant value for our stockholders and will provide important benefits to our customers and employees."
Based in Santa Clara of California, Affymetrix provides products to the customers in various sectors, including life sciences and translational research, molecular diagnostics, reproductive health and agricultural biotechnology.
The firm also offers various antibodies, multiplex RNA, and protein and single-cell assays that serve cytometry market segment, as well as single-cell biology, immunotherapy and infectious disease research.
Affymetrix operates manufacturing facilities in Cleveland, San Diego, US, as well as Vienna of Austria and Singapore.
Image: Thermo Fisher Scientific headquarters in Waltham. Photo: courtesy of Coolcaesar.